Drug Trial Radar · NCT07070440
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jul 16, 2025
Primary completion
Jun 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Dizal PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.
Conditions
- Non Small Cell Lung Cancer
Interventions
DZD6008Drug
DZD6008 was administered orally at 40/60/90 mg QD.
PemetrexedDrug
Pemetrexed 500 mg/m2, every 3 weeks, intravenous infusion.
CarboplatinDrug
Carboplatin AUC 5 mg/mL/min, every 3 weeks, intravenous infusion.
DocetaxelDrug
Docetaxel 75 mg/m2, every 3 weeks, intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Dose-limiting Toxicities (DLTs)Time frame: 21 days after the first dosing
- Number of participants with Adverse events (AEs)/Serious adverse events (SAEs)Time frame: Through the study completion, an average of around 1 year.
- Objective Response Rate (ORR) as assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Time frame: Through the study completion, an average of around 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.